---
title: "Evaxion Biotech Boosts Share Capital With August 2026 ATM ADS Offering"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298032014.md"
description: "Evaxion Biotech raised $2.11 million via an ATM offering of 681,268 ADSs in August 2026, increasing its share capital to DKK 112.77 million. This move strengthens the company's funding position and supports operations through equity authorizations. While analysts rate the stock a 'Buy' with a $16 target, TipRanks’ AI analyst assigns a 'Neutral' rating due to weak financial performance, despite positive clinical updates."
datetime: "2026-09-04T11:28:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298032014.md)
  - [en](https://longbridge.com/en/news/298032014.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298032014.md)
generator: "portal-rs"
---

# Evaxion Biotech Boosts Share Capital With August 2026 ATM ADS Offering

Evaxion Biotech ( (EVAX) ) has shared an update.

Between August 19 and August 21, 2026, Evaxion A/S raised $2.11 million in net proceeds through the sale of 681,268 American Depositary Shares in an at-the-market offering at an average price of $3.1987 per ADS. The transaction increased the company’s registered share capital by nominal DKK 8,515,850 to a total of DKK 112,768,539, and the articles of association were amended effective August 24, 2026 to reflect the larger capital base, modestly strengthening Evaxion’s funding position and capital structure.

The capital raise forms part of Evaxion’s broader use of equity and warrant-based authorizations to support ongoing operations and incentivize management and key employees. By updating its articles to embed the new share capital and existing warrant programs, the company preserves flexibility for future issuances without pre-emptive rights, which may further dilute existing shareholders but provides a mechanism to finance growth and retain talent in a competitive biotech landscape.

The most recent analyst rating on (EVAX) stock is a Buy  
 with a $16.00 price target.  
 To see the full list of analyst forecasts on Evaxion Biotech stock,  
 see the EVAX Stock Forecast page. 

**Spark’s Take on EVAX Stock**

According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.

The score is held back primarily by weak financial performance (ongoing losses, negative cash flow, and volatile small revenue) and only neutral technical setup (below longer-term moving averages). These are partially offset by constructive earnings-call updates on clinical/pipeline progress and reaffirmed runway into H2 2027, though the cash cushion remains limited and funding reliance persists.

To see Spark’s full report on EVAX stock,  
 click here. 

**More about Evaxion Biotech**

Evaxion A/S, which also operates under the names Evaxion Biotech A/S and NovVac A/S, is a Danish biotech company that develops advanced software to enable novel immunotherapies and vaccines. The company’s business model sits at the intersection of biotechnology and artificial intelligence, targeting drug discovery and vaccine development markets.

**Average Trading Volume:** 196,661

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $25.6M

For an in-depth examination of EVAX stock, go to TipRanks’ Overview page.

### Related Stocks

- [EVAX.US](https://longbridge.com/en/quote/EVAX.US.md)

## Related News & Research

- [Evaxion Biotech: Strong R&D progress and financial discipline support a cash runway into H2 2027](https://longbridge.com/en/news/296546698.md)
- [Active Biotech AB (publ) (STO:ACTI): Is Breakeven Near?](https://longbridge.com/en/news/298678959.md)
- [Bellevue’s BB Biotech builds “bibi” AI operating system to support biotech stock-picking process](https://longbridge.com/en/news/298328995.md)
- [Biotech Boss Makes Bold Move With Fresh Insider Buy](https://longbridge.com/en/news/298781404.md)
- [Trinity Biotech publishes 2025 annual report](https://longbridge.com/en/news/298365551.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**